Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction

BACKGROUND: Warfarin treatment has a narrow therapeutic range, requiring meticulous monitoring and dosage titration. Individual dosage requirement has recently partly been explained by genetic variation of the warfarin metabolizing enzyme CYP2C9 and the Vitamin K-activating enzyme VKORC1. In the WAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Haug, Kari Bente Foss, Sharikabad, Mohammad N, Kringen, Marianne K, Narum, Sigrid, Sjaatil, Stine T, Johansen, Per Wiik, Kierulf, Peter, Seljeflot, Ingebjørg, Arnesen, Harald, Brørs, Odd
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Original Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440373/
https://www.ncbi.nlm.nih.gov/pubmed/18559094
http://dx.doi.org/10.1186/1477-9560-6-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440373/
https://www.ncbi.nlm.nih.gov/pubmed/18559094
http://dx.doi.org/10.1186/1477-9560-6-7

Ejemplares similares